BBIO News

Biobeat Brings Leading Hypertension Voices to AHA Hypertension Scientific Sessions as Conversation Shifts to Cuffless 24-Hour Ambulatory Blood Pressure Monitoring

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

The Speak Foundation Announces $300,000 BridgeBio Commitment to Advance Patient-Led LGMD Centers of Excellence

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Condor Software Unveils World's First Clinical Finance AI Agent Purpose-Built for Biopharma R&D

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial